Nonsense mutations outside the splicing consensus mutation, even though the consensus sequences for splicing at both ends of the exon and the beginning of sequence have been reported to cause skipping of the nonsense-containing exon in several human diseases. We intron 15 were unaltered. Exon skipping restored the open reading frame of the mutant transcript and resulted describe, for the first time, nonsense-mediated exon skipping in the laminin α2 (LAMA2) gene. Two siblings in a truncated protein. In cases where the genetic findings do not elucidate the phenotype, mRNA analysis is from a consanguineous family had altered expression of the laminin α2 chain and moderate clinical manifestations. necessary to clarify the primary effect of mutations. Our findings also point to the necessity of immunochemical In both we identified the new nonsense mutation Arg744Stop, which we expected to result in a totally screening for expression of laminin α2 chain in atypical dystrophic adults as well as children. non-functional polypeptide. However, analysis of the transcript revealed skipping of exon 15, containing the Keywords: congenital muscular dystrophy; LAMA2; laminin α2 chain; merosin Abbreviations: EPs ϭ evoked potentials; LAMA2 ϭ laminin α2 chain gene; PCR ϭ polymerase chain reaction
Introduction
Laminins are heterotrimeric proteins, consisting of a heavy matter on MRI (Tomé et al., 1994; Dubowitz and Fardeau, 1995; Philpot et al., 1995) . α chain, and light β and γ chains, which assemble into crossshaped molecules (Engel, 1992; Tryggvason, 1993; Timpl Milder phenotypes have been described in several young patients (Herrmann et al., 1996; Mora et al., 1996; Nissinen and Brown, 1994) . Laminin-2 (merosin) is the isoform of laminin present in the basal lamina of skeletal muscle fibres et al., 1996; Allamand et al., 1997; Hayashi et al., 1997; Sewry et al., 1997; Tan et al., 1997; Cohn et al., 1998; Naom and elsewhere (Leivo et al., 1988; Engvall et al., 1990; Tryggvason, 1993; Sewry et al., 1996) . It contains , 2000 Morandi et al., 1999) , although a genetic defect, usually resulting in partial expression of laminin α2 α2 chain encoded by the laminin α2 (LAMA2) gene on chromosome 6q22 (Vuolteenaho et al., 1994) . Deficient chain, was characterized in only a few (Nissinen et al., 1996; Allamand et al., 1997; Hayashi et al., 1997; , expression of laminin α2 chain is found in many patients with the classic occidental form of congenital muscular 2000). We recently described an adult patient with a myopathy resembling inclusion body myositis and a partial laminin α2 dystrophy (CMD) (Tomé et al., 1994) . CMD due to complete lack of laminin α2 chain is characterized by severe hypotonia chain deficiency due to mutations in the LAMA2 gene (Di Blasi et al., 2000) . at birth associated with an inability to walk unsupported, delayed motor development, high creatine kinase levels and
We describe here, for the first time, exon skipping in the LAMA2 gene mediated by a new nonsense mutation. The a clinically asymptomatic abnormality of the central white mutation is homozygous and occurs in two adult siblings regions, and slight hyperintensity of the cerebellar white matter. from a consanguineous family. Exon skipping restores the open reading frame of the mutant transcript to produce a truncated protein and a mild clinical phenotype.
Immunohistochemistry
Muscle (quadriceps) and skin biopsies were frozen in isopentane cooled in liquid nitrogen and stored in liquid Material and methods nitrogen until use. Immunohistochemical analysis of laminin Subjects α2 chain was performed as described previously (Morandi We studied members of a consanguineous family partially et al., 1999) on 6 µm thick cryosections using two commercial described in Morandi et al. (1999) . The patients gave their monoclonal antibodies: one recognizing the 300 kDa fragment informed consent and the study was approved by the Ethics towards the N-terminus (Alexis, San Diego, Calif., USA), Committee of the Instituto Nazionale Neurologico C, Besta, and the other the 80 kDa fragment towards the C-terminus Milan. The proband (Patient 1) was a 39-year-old man with (Chemicon, Temecula, Calif., USA). mild limb girdle weakness. His symptoms, some difficulty in running and jumping, first appeared at about the age of 15 years and worsened very slowly. He was first examined
Immunoblots
at age 32 years when he complained of limb weakness Expression of laminin α2 chain was evaluated by immunocausing difficulty in getting up from the floor, climbing blotting as described previously (Morandi et al., 1999) 
Molecular analysis
Gower's manoeuvre to get up from the floor, and climbed Genomic DNA, extracted from peripheral blood lymphocytes, stairs with the aid of a hand rail.
was amplified by the polymerase chain reaction (PCR) using Subsequent clinical examinations remained unchanged oligonucleotide primers flanking the intron-exon junctions until age 39, when greater difficulty in walking, rising from of all 64 LAMA2 exons. Amplifications were performed using the floor and climbing stairs became evident. ECG and the PCR touchdown method and conditions were as described echocardiogram were normal, but respiratory function was by Guicheney et al. (1998) . Each amplification employed mildly compromised (forced vital capacity was 81% of that 100 ng of genomic DNA in a 50 µl reaction. The amplification expected). Creatine kinase was about four times above products were resolved electrophoretically on 2% agarose normal. EMG from biceps showed myogenic potentials, gels and purified by the QIAquick PCR Purification Kit and electroneurography revealed motor and sensory nerve (QIAGEN GmbH, Germany). conduction velocities in the lower normal range, and a slightly For SSCP (single strand conformation polymorphism) longer F-wave. Visual and brainstem evoked potentials (EPs) analysis, an aliquot of the PCR product was denatured were normal, while somato-sensory EPs showed mild and separated on a 10% polyacrylamide (acrylamide ϫ 2: abnormalities, suggesting peripheral neuropathy. Motor EPs bisacrylamide ϫ 1, 37.5 : 1) mini-gel at 7 and 20°C. from lower limbs showed mild changes in central motor
Electrophoresis was performed at 8 mA using Hoefer conduction. Brain MRI revealed cerebellar hypotrophy and, apparatus. A silver-staining kit (Biorad, Hercules, Calif., in T 2 weighted images, diffuse white matter hyperintensity USA) was used to visualize the DNA bands on the gels. in periventricular and subcortical areas.
Aberrant conformers were sequenced on both strands using One of the two siblings (Patient 2) of the proband was an Applied Biosystems automated sequencer (Perkin Elmer, similarly affected when first seen at 36 years. She had Foster City, Calif., USA) and the same primers as for the difficulty in walking due to congenital bilateral hip PCR amplification. dislocation, which had been treated surgically. However, neurological examination revealed similar clinical findings to her brother, although they were less severe. Her creatine RNA isolation and complementary DNA kinase was about twice normal. Myopathic changes were detected by EMG, and peripheral nerve involvement was (cDNA) amplification Total RNA was prepared from skeletal muscle using absent. EP studies revealed only a mild reduction in the amplitude of visual EPs. Brain MRI showed a few punctate RNAWIZ TM (Ambion, Austin, Tex., USA). The isolated RNA was reverse transcribed using a First-Strand cDNA Synthesis areas of increased signal in peritrigonal and periventricular Muscle biopsy revealed dystrophic changes in both patients, purified PCR products were subcloned into a pMOSBlue although the muscle specimen from the sister was more vector (Promega, Madison, Wis., USA) and the DNA was severely affected, being characterized by conspicuous fibrotic sequenced using appropriate primers.
and fatty connective tissue proliferation and few surviving fibres.
Immunohistochemical analysis of muscle sections disclosed reduced expression of laminin α2 chain at the
Restriction site analysis
periphery of muscle fibres in Patient 1 (Fig. 1C and D) and The mutation does not introduce a new restriction site in the almost normal expression in the sister ( Fig. 1E and F) . genomic DNA. To determine whether the known HindII sites However, the sister's skin biopsy showed reduced positivity were all present in the patients we performed restriction to laminin α2 chain immunostaining, similar to that in the nuclease (Boehringer Mannheim GmbH, Mannheim, brother's muscle (see Morandi et al., 1999) . Germany) digestion of the region spanning exons 11-16 of On electrophoresis, laminin α2 chain usually runs as 80 LAMA2 cDNA. Ten-microlitre aliquots of the PCR product and 300 kDa fragments (Ehrig et al., 1990) . Immunoblotting of the two patients and of several unaffected controls were using the monoclonal antibody against the 80 kDa fragment digested in a total volume of 20 µl as described by the manufacturers. The products were run on a 3% agarose gel.
revealed a normal sized fragment of altered intensity in both with nonsense mutations (Di Blasi et al., 2000) , splice site mutations (Allamand et al., 1997; Naom et al., 2000) , or a heterozygous insertion in one allele and a deletion in the other, both of which caused frame shifts and stop codons downstream (Hayashi et al., 1997) . In our two cases, we found a new homozygous nonsense mutation in exon 15 and, unexpectedly, partial expression of laminin α2 chain. RNA analysis showed, in addition to the expected transcript, that there was a smaller transcript which arose due to skipping of exon 15, but retained the open reading frame. The smaller RNA was detected exclusively in Patients 1 and 2, and not in the 10 controls we tested, including one LAMA2-mutated patient. Other studies on the (Pegoraro et al., 1996; Allamand et al., 1997; Mendell et al., controls (C).
1998; Pegoraro et al., 1998) . We therefore conclude that the alteration is not a polymorphism.
The smaller transcript was presumably translated to patients, as expected (data not shown). Unfortunately it was not possible, due to lack of material, to quantitate the amount produce a truncated protein lacking 38 amino acids in the IIIb domain. We detected the 80 kDa fragment of the protein of the 80 kDa fragment in relation to a contractile protein.
SSCP analysis revealed abnormal conformers in exon 15 on a Western blot and it was of normal molecular weight as expected. The missing portion of the laminin α2 chain, in the patients and in heterozygous family members compared with controls (Fig. 2) . Direct sequencing of this aberrant towards the N-terminus, should show up as a reduced molecular weight larger fragment, but the antibody against PCR product revealed a new homozygous mutation, a C→T transition at position 2230 of the cDNA sequence, resulting this portion did not detect this fragment on immunoblots.
In some genes, stop mutations have been shown to affect in a stop codon (Arg744Stop) (Fig. 3 ). There were no other alterations in the sequence of exon 15 of the patients or mRNA metabolism and to reduce the amount of detectable mRNA (Satoh et al., 1988; Kadowaki et al., 1990 ; Baserga family members compared with controls. Sequencing of the beginning of intron 15 and of the flanking splice sites Belgrader et al., 1994) . Less commonly, mRNA containing stop mutations is translated, which results in a exon 15 excluded the presence of additional mutations (data not presented).
truncated protein (Lehrmann et al., 1987) . A third possible outcome is that the exon containing the stop mutation is Amplification of the region spanning exons 11-16 from skeletal muscle cDNA showed two bands, one of the expected spliced out of the mature mRNA, which has been demonstrated in several human genetic diseases (Dietz et al., size [663 bp (base pair) ] and one slightly smaller (Fig. 4) . Automated sequencing of the two subcloned PCR products 1993; Hull et al., 1994; Mazoyer et al., 1998; Ars et al., 2000) . This is the first example of nonsense-mediated exon demonstrated a 114 bp in-frame deletion in the smaller fragment due to in-frame skipping of the entire exon 15, skipping to be described in the LAMA2 gene. Exon skipping is a common mutational mechanism, usually which contains the nonsense mutation (Fig. 3) .
HindII restriction analysis of the wild-type exon 11-16 caused by changes in consensus sequences at splice sites or lariat branch-point regions. Sequences outside these regions region produces four fragments of 304, 160, 126 and 73 bp; both patients were shown to have these fragments and an can also affect the inclusion or exclusion of exons and may be located in introns or exons (Green et al., 1986 ; Watakabe additional one of 172 bp, consistent with exon skipping (data not shown).
et Tanaka et al., 1994) . Alternative splicing patterns are determined by the presence of proteins that bind these regulatory sequences (Liu et al., 1997) . Sometimes the quantity of mutant transcript is reduced, which may be due
Discussion
Partial laminin α2 chain deficiency has been reported in to abnormal splice site selection (Dietz et al., 1994) . We suggest that the exon skipping in our family may be due several cases of CMD, and the clinical picture is usually milder than in patients totally lacking the protein (Herrmann to disruption of the purine-rich splicing enhancer sequence by the nonsense mutation. This mechanism has been et al ., 1996; Mora et al., 1996; Allamand et al., 1997; Hayashi et al., 1997; Sewry et al., 1997; Tan et al., 1997;  demonstrated in the dystrophin gene (Shiga et al., 1997) by experimentally substituting a nucleotide of the purine-rich Cohn et al., 1998; Naom et al., 1998 Naom et al., , 2000 Morandi et al., 1999; Di Blasi et al., 2000) . In the few cases characterized, splicing enhancer sequence with a thymine, creating a nonsense mutation. In our patients, the C→T transition takes the LAMA2 gene defects were missense mutations, which were homozygous (Nissinen et al., 1996) or associated place in a purine-rich sequence, which is very likely to be the splicing enhancer sequence. As well as in the dystrophin gene (Shiga et al., 1997) , exon skipping mediated by a nonsense mutation disrupting the splicing enhancer sequence has been described in the 3-hydroxy-3-methylglutaryl-CoA lyase gene (Pié et al., 1997) and in the adenosine deaminase gene (Santisteban et al., 1995) . Exon skipping within the LAMA2 gene has been reported previously in two siblings from a consanguineous family (Allamand et al., 1997) : a mutation in the splice consensus sequence resulted in the skipping of exon 25, so that the predicted protein lacked 63 amino acids of domain IVa. The patients partially expressed laminin α2 chain and were mildly affected. The in-frame deletions found in our patients and in those of Allamand et al. occur in domains not involved in laminin trimer formation, and, therefore, it is not surprising that in both cases a semi-functional protein is produced, resulting in mild dystrophin and dystrophin-associated proteins.
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